DB
BCRX icon

Danske Bank’s BioCryst Pharmaceuticals BCRX Stock Holding History

Danske Bank’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20 Hold
2
– – ﹤0.01% 1049
2026
Q1 		$19 Buy
+2
New +$16 ﹤0.01% 1068
2025
Q3 		– Sell
-700
Closed -$6.27K – 1498
2025
Q2 		$6.27K Sell
700
-192,864
-100% -$1.8M ﹤0.01% 1323
2025
Q1 		$1.45M Buy
+193,564
New +$1.56M ﹤0.01% 761

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Danske Bank's BCRX Position: Q2 2026 in Review

Danske Bank held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 2 shares worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #1049.

Danske Bank first reported a position in BCRX in Q1 2025 and has held it in 4 quarters since. The position peaked at $1.45M in Q1 2025. 225 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Danske Bank held 2 shares of BioCryst Pharmaceuticals worth $20 as of Q2 2026.
  • Danske Bank left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1049 holding.
  • Danske Bank first reported a position in BioCryst Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • Danske Bank's BioCryst Pharmaceuticals position peaked at $1.45M in Q1 2025.
  • 225 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.